Kanghua Bio: Nametex RSV Vaccine Initiates Phase II Clinical Trial
Kanghua Bio announced that its subsidiary, Naimi Xin, has initiated Phase II clinical trials for its self-developed lyophilized respiratory syncytial virus (RSV) mRNA vaccine. This development marks a significant step in the vaccine's progression through clinical testing. The company is also involved in other market activities, including regulatory oversight of abnormal stock trading. AI